ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1912

Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement

Emmerik F.A. Leijten1,2, Tessa S. van Kempen1,2, Michel A.M. Olde Nordkamp1,2, Fleurieke H. Verhagen2,3, Sanne Hiddingh2,3, Jonas J.W. Kuiper2,3, Marianne L. Boes2,4 and Timothy R.D.J. Radstake1,2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Chemokine Receptors, chemokines, psoriasis and psoriatic arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso) are exceedingly scarce, particularly in patients without immune-modulatory medications that confound results. A head-to-head comparison of the immune cell composition in PsA and Pso is an essential step to understand the development of rheumatic manifestations in patients with psoriasis.

Methods: Blood samples and clinical parameters were collected from 23 healthy controls (HC), 21 patients with psoriasis in whom psoriatic arthritis was excluded by a rheumatologist (Pso), 21 patients with psoriatic arthritis meeting CASPAR criteria (PsA) and 16 patients with ankylosing spondylitis meeting ASAS criteria but without psoriasis (AS). The Pso and PsA cohorts were matched for age, gender, CRP, ESR, psoriasis duration and psoriasis skin severity. All patients were free from biological or conventional DMARD therapy. Using a highly standardized flow-cytometric protocol the peripheral blood mononuclear cells (PBMCs) from patients and controls underwent extensive extracellular and intracellular immunophenotyping capable of detecting over 110 different myeloid and lymphoid cell subsets / populations. In synovial fluid (SF) samples from patients with psoriatic arthritis the level of CCL27 was determined using Luminex Technology and the presence of CCR10+ CD8 T cells was evaluated by flow-cytometry.

Results: The overall phenotype and immune cell composition showed remarkable overlap in PsA and Pso, with both cohorts characterized by an increase in the frequency of regulatory T cells, an increase in IL-17A & IL-22 co-producing CD4 and CD8 T cells, a decrease in plasmacytoid dendritic cells, and a decrease in mucosal-associated invariant T (MAIT)-like cells. Only one specific cell population differentiated the PsA from Pso cohort: CCR10+ CD8 T cells, being enriched in PsA as compared to Pso (Figure 1). These CCR10+ CD8 T cells had an effector memory status, were CXCR3-CCR6- and predominantly co-expressed CCR4. While the CCR4+ CD8 T cell frequencies were positively correlated to psoriasis skin severity, the CCR10+ CD8 T cell frequencies were not related to skin severity. Analysis of SF samples from psoriatic arthritis patients confirmed the presence of CCL27, the ligand for CCR10 receptor, and the expression of CCR10 on SF CD8 T cells.

Conclusion: A broad immunophenotyping strategy has revealed a potentially novel role for CD8 T cells expressing CCR10 to mediate the progression from cutaneous disease to joint disease in psoriatic arthritis. Further functional studies are needed to investigate the role these cells play in the different compartments affected by the disease.


Disclosure: E. F. A. Leijten, None; T. S. van Kempen, None; M. A. M. Olde Nordkamp, None; F. H. Verhagen, None; S. Hiddingh, None; J. J. W. Kuiper, None; M. L. Boes, None; T. R. D. J. Radstake, None.

To cite this abstract in AMA style:

Leijten EFA, van Kempen TS, Olde Nordkamp MAM, Verhagen FH, Hiddingh S, Kuiper JJW, Boes ML, Radstake TRDJ. Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/broad-immunophenotyping-results-ccr10-expressing-cd8-t-cells-distinguish-psoriatic-arthritis-from-psoriasis-limited-to-skin-involvement/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/broad-immunophenotyping-results-ccr10-expressing-cd8-t-cells-distinguish-psoriatic-arthritis-from-psoriasis-limited-to-skin-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology